GC
CLVS

Guggenheim Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Guggenheim Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-145,108
Closed -$570K – 2194
2019
Q3 		$570K Buy
145,108
+60,278
+71% +$488K ﹤0.01% 1562
2019
Q2 		$1.26M Buy
84,830
+14,533
+21% +$263K 0.01% 1242
2019
Q1 		$1.75M Sell
70,297
-9,323
-12% -$234K 0.01% 1133
2018
Q4 		$1.43M Buy
79,620
+3,389
+4% +$69.2K 0.01% 1211
2018
Q3 		$2.24M Buy
76,231
+11,596
+18% +$449K 0.01% 1183
2018
Q2 		$2.94M Buy
64,635
+9,780
+18% +$476K 0.02% 1025
2018
Q1 		$2.9M Buy
54,855
+2,262
+4% +$132K 0.01% 1379
2017
Q4 		$3.58M Sell
52,593
-15,249
-22% -$1.07M 0.01% 1233
2017
Q3 		$5.59M Buy
67,842
+12,840
+23% +$1.02M 0.01% 1000
2017
Q2 		$5.15M Buy
55,002
+4,003
+8% +$245K 0.01% 1002
2017
Q1 		$3.25M Sell
50,999
-12,569
-20% -$764K 0.01% 1291
2016
Q4 		$2.82M Buy
+63,568
New +$2.24M 0.01% 1415
2016
Q2 		– Sell
-104,121
Closed -$2M – 2950
2016
Q1 		$2M Sell
104,121
-12,987
-11% -$275K 0.01% 1571
2015
Q4 		$4.1M Buy
117,108
+25,241
+27% +$1.63M 0.01% 1114
2015
Q3 		$8.45M Sell
91,867
-12,609
-12% -$1.09M 0.03% 820
2015
Q2 		$9.18M Buy
104,476
+6,585
+7% +$564K 0.02% 873
2015
Q1 		$7.27M Buy
97,891
+2,890
+3% +$204K 0.02% 996
2014
Q4 		$5.32M Buy
95,001
+9,814
+12% +$516K 0.01% 1096
2014
Q3 		$3.86M Buy
85,187
+2,686
+3% +$112K 0.01% 1353
2014
Q2 		$3.42M Buy
82,501
+8,569
+12% +$441K 0.01% 1413
2014
Q1 		$5.12M Buy
73,932
+2,910
+4% +$214K 0.01% 1110
2013
Q4 		$4.28M Buy
71,022
+9,982
+16% +$543K 0.01% 1176
2013
Q3 		$3.71M Buy
+61,040
New +$4.33M 0.01% 1251

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Guggenheim Capital's CLVS Position: Q4 2019 in Review

Guggenheim Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2019, closing a stake of 145,108 shares — an estimated $570K sold.

Guggenheim Capital first reported a position in CLVS in Q3 2013 and held it in 23 quarters. The position peaked at $9.18M in Q2 2015. 147 funds tracked by Wall St. Rank hold CLVS as of Q4 2019.

  • Guggenheim Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2019 after selling out during the quarter.
  • Guggenheim Capital sold 145,108 Clovis Oncology, Inc. shares in Q4 2019, an estimated $570K.
  • Guggenheim Capital first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 23 quarters.
  • Guggenheim Capital's Clovis Oncology, Inc. position peaked at $9.18M in Q2 2015.
  • 147 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2019.

Based on Guggenheim Capital's 13F filing for Q4 2019, filed 14 Feb 2020.